%	O
%	O
TITLE	O

Young	O
adult	O
patients	O
with	O
squamous	O
cell	O
carcinoma	O
of	O
the	O
tongue	O
strongly	O
express	O
p16	O
without	O
human	O
papillomavirus	O
infection	O
.	O

%	O
%	O
ABSTRACT	O

Long	O
-	O
term	O
smoking	O
and	O
drinking	O
are	O
known	O
to	O
contribute	O
to	O
the	O
onset	O
of	O
tongue	O
cancer	O
(	O
TC	O
)	O
.	O

However	O
,	O
the	O
increasing	O
incidence	B-Incidence_or_Prevalence
of	O
TC	O
in	O
younger	O
adults	O
has	O
been	O
suggested	O
to	O
be	O
associated	O
with	O
other	O
factors	O
.	O
The	O
present	O
study	O
investigated	O
the	O
relationship	O
between	O
TC	O
and	O
human	O
papillomavirus	O
(	O
HPV	O
)	O
infection	O
.	O
Clinical	O
records	O
and	O
surgically	O
resected	O
specimens	B-HPV_Sample_Type
from	O
86	B-Study_Cohort
patients	I-Study_Cohort
(	I-Study_Cohort
<	I-Study_Cohort
40	I-Study_Cohort
-	I-Study_Cohort
years	I-Study_Cohort
-	I-Study_Cohort
old	I-Study_Cohort
,	I-Study_Cohort
nâ€‰=â€‰12	I-Study_Cohort
;	I-Study_Cohort
â‰¥40	I-Study_Cohort
-	I-Study_Cohort
years	I-Study_Cohort
-	I-Study_Cohort
old	I-Study_Cohort
,	I-Study_Cohort
nâ€‰=â€‰74	I-Study_Cohort
)	I-Study_Cohort
with	I-Study_Cohort
TC	I-Study_Cohort
were	O
analyzed	O
.	O

Strong	O
nuclear	O
and	O
cytoplasmic	O
p16	O
staining	O
was	O
considered	O
positive	O
.	O

HPV	O
DNA	O
(	O
high	O
-	O
risk	O
subtypes	O
:	O
16	O
,	O
18	O
,	O
31	O
,	O
33	O
,	O
35	O
,	O
52b	O
,	O
and	O
58	O
;	O
low	O
-	O
risk	O
subtypes	O
:	O
6	O
and	O
11	O
)	O
was	O
detected	O
using	O
consensus	B-HPV_Lab_Technique
primer	I-HPV_Lab_Technique
-	I-HPV_Lab_Technique
mediated	I-HPV_Lab_Technique
polymerase	I-HPV_Lab_Technique
chain	I-HPV_Lab_Technique
reaction	I-HPV_Lab_Technique
.	I-HPV_Lab_Technique
Strong	O
p16	O
expression	O
was	O
observed	O
in	O
10	O
(	O
11	O
.	O
6	O
%	O
)	O
patients	O
.	O

HPV	O
DNA	O
was	O
detected	O
in	O
9	O
(	O
10	O
.	O
5	O
%	O
)	O
patients	O
(	O
high	O
-	O
risk	O
subtypes	O
,	O
nâ€‰=â€‰2	O
;	O
low	O
-	O
risk	O
subtypes	O
,	O
nâ€‰=â€‰7	O
)	O
.	O

Strong	O
p16	O
expression	O
was	O
observed	O
more	O
frequently	O
among	O
younger	O
adults	O
than	O
among	O
older	O
adults	O
(	O
33	O
.	O
3	O
%	O
vs	O
.	O
8	O
.	O
1	O
%	O
;	O
pâ€‰=â€‰	O
.	O
045	O
)	O
.	O
p16	O
staining	O
did	O
not	O
correlate	O
with	O
the	O
detection	O
of	O
HPV	O
DNA	O
(	O
correlation	O
coefficient	O
,	O
0	O
.	O
113	O
;	O
pâ€‰=â€‰	O
.	O
300	O
)	O
.	O

In	O
TC	O
,	O
p16	O
expression	O
was	O
not	O
associated	O
with	O
HPV	O
infection	O
,	O
suggesting	O
that	O
it	O
may	O
be	O
caused	O
by	O
a	O
different	O
mechanism	O
.	O

%	O
%	O
MATERIALS	O
AND	O
METHODS	O

Patients	O

The	O
clinical	O
records	O
of	O
86	B-Study_Cohort
Japanese	I-Study_Cohort
patients	I-Study_Cohort
(	I-Study_Cohort
<	I-Study_Cohort
40	I-Study_Cohort
-	I-Study_Cohort
years	I-Study_Cohort
-	I-Study_Cohort
old	I-Study_Cohort
,	I-Study_Cohort
n	I-Study_Cohort
12	I-Study_Cohort
;	I-Study_Cohort
40	I-Study_Cohort
-	I-Study_Cohort
years	I-Study_Cohort
-	I-Study_Cohort
old	I-Study_Cohort
,	I-Study_Cohort
n	I-Study_Cohort
74	I-Study_Cohort
)	I-Study_Cohort
,	I-Study_Cohort
treated	I-Study_Cohort
for	I-Study_Cohort
TC	I-Study_Cohort
at	O
our	O
institu	O
-	O
tion	O
between	O
2001	B-Study_Time
and	I-Study_Time
2015	I-Study_Time
,	I-Study_Time
were	O
analyzed	O
.	O

Tumors	O
origi	O
-	O
nating	O
from	O
the	O
base	O
of	O
the	O
tongue	O
were	O
excluded	O
.	O

The	O
cohort	O
comprised	O
57	O
men	O
and	O
29	O
women	O
,	O
with	O
a	O
mean	O
age	O
at	O
diagnosis	O
of	O
60	O
.	O
2	O
(	O
range	O
:	O
23–96	O
)	O
years	O
.	O

Smoking	O
status	O
was	O
confirmed	O
in	O
82	O
patients	O
,	O
including	O
47	O
(	O
57	O
.	O
3	O
%	O
)	O
who	O
were	O
smokers	O
or	O
ex	O
-	O
smokers	O
.	O

Alcohol	O
consumption	O
was	O
also	O
confirmed	O
in	O
81	O
patients	O
,	O
including	O
39	O
(	O
48	O
.	O
1	O
%	O
)	O
who	O
were	O
current	O
drinkers	O
or	O
ex	O
-	O
drinkers	O
.	O

The	O
86	O
patients	O
had	O
squamous	O
cell	O
carcinomas	O
(	O
SCCs	O
)	O
,	O
staged	O
according	O
to	O
the	O
2009	O
Union	O
for	O
International	O
Cancer	O
Control	O
Tumor	O
-	O
Node	O
-	O
Metastasis	O
classification	O
.	O

Positive	O
lymph	O
nodes	O
were	O
defined	O
as	O
nodes	O
detected	O
on	O
computed	O
tomography	O
and	O
/	O
or	O
magnetic	O
resonance	O
imaging	O
and	O
18F	O
-	O
fluorodeoxyglucose	O
positron	O
emission	O
tomography	O
.	O

Of	O
the	O
86	O
patients	O
with	O
TC	O
,	O
37	O
(	O
43	O
.	O
0	O
%	O
)	O
had	O
Stage	O
I	O
disease	O
,	O
13	O
(	O
15	O
.	O
1	O
%	O
)	O
had	O
Stage	O
II	O
disease	O
,	O
13	O
(	O
15	O
.	O
1	O
%	O
)	O
had	O
Stage	O
III	O
disease	O
,	O
and	O
23	O
(	O
26	O
.	O
8	O
%	O
)	O
had	O
Stage	O
IV	O
disease	O
.	O

IHC	O
staining	O

Paraffin	O
-	O
embedded	O
tissue	B-HPV_Sample_Type
sections	B-HPV_Sample_Type
were	O
used	O
for	O
IHC	B-HPV_Lab_Technique
stain	O
-	O
ing	O
using	O
the	O
CDKN2A	O
/	O
p16INK4a	O
antibody	O
(	O
EPR1473	O
)	O
(	O
dilution	O
1	O
:	O
200	O
;	O
Abcam	O
,	O
Cambridge	O
,	O
UK	O
)	O
and	O
an	O
automated	O
Bond	O
Max	O
stainer	O
(	O
Leica	O
Biosystems	O
,	O
Wetzlar	O
,	O
Germany	O
)	O
.	O

p16	O
staining	O
intensity	O
was	O
scored	O
as	O
0	O
(	O
negative	O
)	O
,	O
1	O
(	O
weak	O
nuclear	O
staining	O
)	O
,	O
or	O
2	O
(	O
moderate	O
to	O
strong	O
nuclear	O
and	O
cytoplasmic	O
staining	O
)	O
(	O
)	O
.	O

According	O
to	O
the	O

classification	O
proposed	O
by	O
Orita	O
et	O
al	O
.	O
[	O
]	O
,	O
scores	O
of	O
0	O
or	O
1	O
were	O
considered	O
negative	O
and	O
2	O
was	O
considered	O
positive	O
.	O

HPV	B-HPV_Lab_Technique
DNA	I-HPV_Lab_Technique
testing	I-HPV_Lab_Technique

HPV	O
DNA	O
was	O
detected	O
using	O
consensus	B-HPV_Lab_Technique
primer	I-HPV_Lab_Technique
-	I-HPV_Lab_Technique
mediated	I-HPV_Lab_Technique
polymerase	I-HPV_Lab_Technique
chain	I-HPV_Lab_Technique
reaction	I-HPV_Lab_Technique
(	I-HPV_Lab_Technique
PCR	I-HPV_Lab_Technique
)	I-HPV_Lab_Technique
assays	I-HPV_Lab_Technique
.	O

DNA	O
was	O
extracted	O
from	O
paraffin	O
-	O
embedded	O
tissue	B-HPV_Sample_Type
sections	B-HPV_Sample_Type
using	O
the	O
QIAamp	O
DNA	O
Micro	O
Kit	O
(	O
QIAGEN	O
,	O
Valencia	O
,	O
CA	O
)	O
and	O
quantified	O
using	O
a	O
NanoDropVND	O
-	O
1000	O
spectrophotometer	O
(	O
Thermo	O
Fisher	O
Scientific	O
,	O
Wilmington	O
,	O
DE	O
)	O
.	O

PCR	B-HPV_Lab_Technique
was	I-HPV_Lab_Technique
performed	I-HPV_Lab_Technique
with	I-HPV_Lab_Technique
reference	I-HPV_Lab_Technique
to	I-HPV_Lab_Technique
the	I-HPV_Lab_Technique
TaKaRa	I-HPV_Lab_Technique
PCR	I-HPV_Lab_Technique
Human	I-HPV_Lab_Technique
Papillomavirus	I-HPV_Lab_Technique
Typing	I-HPV_Lab_Technique
Set	I-HPV_Lab_Technique
(	I-HPV_Lab_Technique
Takara	I-HPV_Lab_Technique
Bio	I-HPV_Lab_Technique
,	I-HPV_Lab_Technique
Tokyo	I-HPV_Lab_Technique
,	I-HPV_Lab_Technique
Japan	I-HPV_Lab_Technique
)	O
.	O

The	O
following	O
pri	O
-	O
mers	O
were	O
used	O
:	O

High	O
-	O
risk	O
forward	O
primer	O
:	O
50	O
-	O
TGTCAAAAACCGTTGTGTCC	O
-	O
30	O
Low	O
-	O
risk	O
forward	O
primer	O
:	O
50	O
-	O
TGCTAATTCGGTGCTACCTG	O
-	O
30	O

Consensus	O
primer	O
:	O
50	O
-	O
GAGCTGTCGCTTAATTGCTC	O
-	O
30	O

The	O
consensus	O
primer	O
was	O
fluorescently	O
labeled	O
.	O

HPV	O
DNA	O
(	O
high	O
-	O
risk	O
subtypes	O
:	O
16	O
,	O
18	O
,	O
31	O
,	O
33	O
,	O
35	O
,	O
52b	O
,	O
and	O
58	O
;	O
low	O
-	O
risk	O
subtypes	O
:	O
6	O
and	O
11	O
)	O
was	O
detected	O
using	O
these	O
primers	O
(	O
Sigma	O
-	O
Aldrich	O
,	O
Tokyo	O
,	O
Japan	O
)	O
.	O

The	O
PCR	B-HPV_Lab_Technique
products	O
were	O
analyzed	O
using	O
an	O
ABI	O
PRISMV310	O
Genetic	O
Analyzer	O
(	O
Applied	O
Biosystems	O
,	O
Foster	O
City	O
,	O
CA	O
)	O
with	O
GeneScan	O
and	O
GeneMapper	O
software	O
(	O
Applied	O
Biosystems	O
,	O
Foster	O
City	O
,	O
CA	O
)	O
.	O

Treatment	O

Although	O
treatments	O
were	O
chosen	O
at	O
the	O
discretion	O
of	O
the	O
attend	O
-	O
ing	O
physician	O
,	O
all	O
86	O
patients	O
underwent	O
surgical	O
resections	O
.	O

Additional	O
treatments	O
included	O
:	O
Stage	O
I	O
:	O
surgery	O
only	O
(	O
n	O
¼	O
32	O
)	O
,	O
neoadjuvant	O
chemotherapy	O
(	O
n	O
¼	O
2	O
)	O
,	O
and	O
adjuvant	O
chemotherapy	O
(	O
n	O
¼	O
3	O
)	O
;	O
Stage	O
II	O
:	O
surgery	O
only	O
(	O
n	O
¼	O
9	O
)	O
,	O
postoperative	O
radiother	O
-	O
apy	O
(	O
n	O
¼	O
1	O
)	O
,	O
neoadjuvant	O
chemotherapy	O
(	O
n	O
¼	O
1	O
)	O
,	O
adjuvant	O
chemotherapy	O
(	O
n	O
¼	O
1	O
)	O
,	O
and	O
neoadjuvant	O
and	O
adjuvant	O
chemo	O
-	O
therapy	O
(	O
n	O
¼	O
1	O
)	O
;	O
Stage	O
III	O
:	O
surgery	O
only	O
(	O
n	O
¼	O
2	O
)	O
,	O
preoperative	O
radiotherapy	O
(	O
n	O
¼	O
1	O
)	O
,	O
neoadjuvant	O
chemotherapy	O
(	O
n	O
¼	O
5	O
)	O
,	O
and	O
neoadjuvant	O
and	O
adjuvant	O
chemotherapy	O
(	O
n	O
¼	O
5	O
)	O
;	O
and	O
Stage	O
IV	O
,	O
neoadjuvant	O
chemotherapy	O

(	O
n	O
¼	O
12	O
)	O
,	O
adjuvant	O
chemotherapy	O
(	O
n	O
¼	O
1	O
)	O
,	O
postoperative	O
chemoradiotherapy	O
(	O
n	O
¼	O
1	O
)	O
,	O
neoadjuvant	O

82	O
T	O
.	O

TACHIBANA	O
ET	O
AL	O
.	O

Table	O
1	O
.	O

Univariate	O
analysis	O
of	O
factors	O
linked	O
to	O
p16	O
staining	O
and	O
HPV	O
infection	O
.	O

p16	O
(	O
2	O
:	O
2	O
)	O
HPV	O
high	O
or	O
low	O
risk	O
(	O
PCR	O
)	O

<	O
40	O

Drinker	O

HPV	O
:	O
human	O
papillomavirus	O
;	O
PCR	B-HPV_Lab_Technique
:	I-HPV_Lab_Technique
polymerase	I-HPV_Lab_Technique
chain	I-HPV_Lab_Technique
reaction	I-HPV_Lab_Technique
;	O
n	O
:	O
number	O
of	O
cases	O
.	O

and	O
adjuvant	O
chemotherapy	O
(	O
n	O
7	O
)	O
,	O
neoadjuvant	O
and	O
postoper	O
-	O
ative	O
chemoradiotherapy	O
(	O
n	O
1	O
)	O
,	O
and	O
neoadjuvant	O
chemother	O
-	O
apy	O
and	O
postoperative	O
bioradiotherapy	O
(	O
n	O
1	O
)	O
.	O

The	O
chemotherapy	O
regimens	O
mainly	O
comprised	O
cisplatin	O
or	O
nedapla	O
-	O
tin	O
and	O
5	O
-	O
fluorouracil	O
,	O
with	O
the	O
occasional	O
inclusion	O
of	O
docetaxel	O
.	O

Tegafur	O
/	O
gimeracil	O
/	O
oteracil	O
was	O
sometimes	O
administered	O
as	O
a	O
sub	O
-	O
stitute	O
for	O
these	O
agents	O
,	O
according	O
to	O
the	O
patients’	O
age	O
,	O
disease	O
stage	O
,	O
and	O
performance	O
status	O
.	O

In	O
instances	O
where	O
the	O
tumor	O
did	O
not	O
exhibit	O
a	O
complete	O
response	O
or	O
had	O
recurred	O
following	O
initial	O
treatment	O
,	O
additional	O
treatments	O
were	O
administered	O
.	O

Patients	O
were	O
followed	O
until	O
their	O
death	O
or	O
their	O
last	O
clinical	O
evaluation	O
(	O
range	O
:	O
1–140	O
months	O
;	O
mean	O
:	O
37	O
.	O
6	O
months	O
)	O
.	O

During	O
follow	O
-	O
up	O
,	O
37	O
patients	O
(	O
43	O
.	O
0	O
%	O
)	O
showed	O
recurrence	O
after	O
the	O
initial	O
surgical	O
treatment	O
;	O
loco	O
-	O
regional	O
recurrence	O
was	O
observed	O
in	O
15	O
cases	O
(	O
17	O
.	O
4	O
%	O
)	O
,	O
20	O
(	O
23	O
.	O
3	O
%	O
)	O
had	O
neck	O
metastasis	O
,	O
and	O
12	O
(	O
14	O
.	O
0	O
%	O
)	O
had	O
distant	O
metastasis	O
.	O

Statistical	O
analyses	O

Differences	O
in	O
baseline	O
characteristics	O
were	O
assessed	O
using	O
Fisher’s	O
exact	O
test	O
.	O

Survival	O
was	O
defined	O
as	O
the	O
time	O
interval	O
between	O
the	O
date	O
of	O
diagnosis	O
and	O
the	O
date	O
of	O
death	O
or	O
last	O
follow	O
-	O
up	O
.	O

Survival	O
was	O
estimated	O
using	O
the	O
Kaplan–Meier	O
method	O
and	O
compared	O
using	O
the	O
log	O
-	O
rank	O
test	O
;	O
patients	O
lost	O
to	O
follow	O
-	O
up	O
were	O
censored	O
.	O

p	O
<	O
.	O
05	O
was	O
considered	O
statistic	O
-	O
ally	O
significant	O
.	O

The	O
study	O
protocol	O
was	O
approved	O
by	O
the	O
Institutional	O
Review	O
Board	O
of	O
Okayama	O
University	O
(	O
Okayama	O
,	O
Japan	O
)	O
.	O

All	O
patients	O
were	O
Japanese	O
and	O
provided	O
written	O
informed	O
con	O
-	O
sent	O
prior	O
to	O
treatment	O
.	O

